![]() |
**__Related stories:__***linkurl:Strangling the experimentalists: Opinion;http://www.the-scientist.com/news/display/57137/
[8th February 2010]*linkurl:"Study ethics, NIH!";http://www.the-scientist.com/blog/display/56151/
[17th November 2009]
Administrators at Sweden's premier medical university, the Karolinska Institute, announced today (March 2nd) that they've fired the institution's dean of research for exerting "undue influence" over the allocation of funds to top Karolinska professors.Image: Camilla Svensk Clinical pathologist linkurl:Karl Tryggvason;http://ki.se/ki/jsp/polopoly.jsp?d=17271&l=en reportedly tried to influence the decisions of an independent panel regarding which researchers at the Karolinska Institute should rec
![]() |


From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.
View Full Profile
The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.


In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.

In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.


Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.


Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.

Collaboration will bring next generation orchestration and modular automation to scientists worldwide

The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.

Partnership unites AI and single cell technology to map immune dysfunction and improve drug discovery and development outcomes